Margetuximab

What Is Margetuximab?

• Margetuximab (Margenza) is a HER2/neu receptor antagonist.

What are the uses of this medicine?

• Margetuximab (Margenza) is indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.

How does this medicine work?

• Margetuximab-cmkb binds to the extracellular domain of the human epidermal growth factor receptor 2 protein (HER2).
• Upon binding to HER2-expressing tumor cells, margetuximab-cmkb inhibits tumor cell proliferation, reduces shedding of the HER2 extracellular domain and mediates antibody-dependent cellular cytotoxicity (ADCC).

Who Should Not Use this medicine ?

• This medicine have no usage limitations

Is this medicine FDA approved?

• It was approved for use in the United States in 2020.

How should this medicine be used?

• Administer Margenza as an intravenous infusion at 15 mg/kg over 120 minutes for the initial dose, then over a minimum of 30 minutes every 3 weeks for all subsequent doses.
• On days when both Margenza and chemotherapy are to be administered, Margenza may be administered immediately after chemotherapy completion.

What are the dosage forms and brand names of this medicine?

This medicine is available in fallowing doasage form: As injections: 250 mg/10 mL (25 mg/mL) in a single-dose vial

This medicine is available in fallowing brand namesː

• Margenza

What side effects can this medication cause?

Common possible side effects and laboratory abnormalities of this medicine include:

• fatigue/asthenia
• nausea
• diarrhea
• vomiting
• constipation
• headache
• pyrexia
• alopecia
• abdominal pain
• peripheral neuropathy
• arthralgia/myalgia
• cough
• decreased appetite
• dyspnea
• infusion-related reactions
• palmar-plantar erythrodysesthesia* extremity pain

What special precautions should I follow?

• Margenza may lead to reductions in left ventricular ejection fraction (LVEF).
• Evaluate cardiac function prior to and during treatment.
• Discontinue Margenza treatment for a confirmed clinically significant decrease in left ventricular function.
• Margenza can cause fetal harm when administered to a pregnant woman.
• Advise patients of the risk and need for effective contraception.
• If a significant infusion-associated reaction occurs, slow or interrupt the infusion and administer appropriate medical therapies.

What to do in case of emergency/overdose?

• In case of overdose, call the poison control helpline of your country. In the United States, call 1-800-222-1222.

• Overdose related information is also available online at poisonhelp.org/help.
• In the event that the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services. In the United States, call 911.

Can this medicine be used in pregnancy?

• Exposure to Margenza during pregnancy can cause embryo-fetal harm.

Can this medicine be used in children?

• Safety and effectiveness of Margenza have not been established in pediatric patients.

What should I know about storage and disposal of this medication?

• Store vials refrigerated at 2°C to 8°C (36°F to 46°F) in original carton to protect from light until time of use.
• Do not freeze.
• Do not shake.

   This article is a monoclonal antibody–related stub. You can help WikiMD by expanding it!

• Dailymed label info on Margetuximab
• FDA Margetuximab